Format
Sort by
Items per page

Send to

Choose Destination

Best matches for cholesterol AND cholestyramine AND fluvastatin AND ldl cholesterol lipoproteins:

Search results

Items: 1 to 20 of 29

1.

The cost effectiveness of statin therapies in Spain in 2010, after the introduction of generics and reference prices.

Plans-RubiĆ³ P.

Am J Cardiovasc Drugs. 2010;10(6):369-82. doi: 10.2165/11539150-000000000-00000.

PMID:
21090830
2.

Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.

Plans-RubiĆ³ P.

Am J Cardiovasc Drugs. 2006;6(3):177-88.

PMID:
16780391
3.

Effects of cholestyramine on vitamin E levels in patients treated with statins.

Kersting F, Selenka A, Walch S.

J Clin Pharmacol. 2000 Dec;40(12 Pt 2):1476-9.

PMID:
11185669
4.

A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.

Hilleman DE, Phillips JO, Mohiuddin SM, Ryschon KL, Pedersen CA.

Clin Ther. 1999 Mar;21(3):536-62.

PMID:
10321422
6.

Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]).

Herd JA, Ballantyne CM, Farmer JA, Ferguson JJ 3rd, Jones PH, West MS, Gould KL, Gotto AM Jr.

Am J Cardiol. 1997 Aug 1;80(3):278-86.

PMID:
9264419
7.

The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia.

West MS, Herd JA, Ballantyne CM, Pownall HJ, Simpson S, Gould L, Gotto AM Jr.

Control Clin Trials. 1996 Dec;17(6):550-83.

PMID:
8974213
8.

Fluvastatin in combination with other lipid-lowering agents.

Jokubaitis LA.

Br J Clin Pract Suppl. 1996 Jan;77A:28-32. Review.

PMID:
8729588
9.

The patient at risk: who should we be treating?

Shviro I, Leitersdorf E.

Br J Clin Pract Suppl. 1996 Jan;77A:24-7. Review.

PMID:
8729587
11.
12.

Currently available hypolipidaemic drugs and future therapeutic developments.

Farmer JA, Gotto AM Jr.

Baillieres Clin Endocrinol Metab. 1995 Oct;9(4):825-47. Review.

PMID:
8593127
13.
14.

Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.

Leitersdorf E, Muratti EN, Eliav O, Peters TK.

Am J Cardiol. 1995 Jul 13;76(2):84A-88A.

PMID:
7604807
15.

High-dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolemia.

Eliav O, Schurr D, Pfister P, Friedlander Y, Leitersdorf E.

Am J Cardiol. 1995 Jul 13;76(2):76A-79A.

PMID:
7604804
16.
17.

Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group.

Bard JM, Ose L, Hagen E, Duriez P, Pfister P, Fruchart JC, Dallongeville J.

Am J Cardiol. 1995 Jul 13;76(2):65A-70A.

PMID:
7604802
18.
19.
20.

Fluvastatin in combination with other lipid-lowering agents.

Jokubaitis LA.

Br J Clin Pract Suppl. 1994 Dec;(77):28-32. Update in: Br J Clin Pract Suppl. 1996 Jan;77A:28-32.

PMID:
19496270

Supplemental Content

Loading ...
Support Center